The drug industry is front and center in a national dialogue. How do we make sure patients around the world can get the medicines they need? Can we balance costs and the need for innovation? Pharma leaders answer Forbes’ questions – and yours.

“Millions of Americans rely on prescription drugs to get and stay healthy. The challenges of dealing with a health condition are only made worse when pharmaceutical companies take advantage of patients and raising prices where they see an increased market opportunity,” said CSRxP Executive Director John Rother.

The American Diabetes Association’s board of directors is calling on Congress to hold hearings to investigate dramatic increases in insulin prices and to take action to ensure that people have affordable access to the essential drug.

“The newly-elected Congress has a mandate to pass market-based solutions, such as legislation that would give patients more choices in their medications. Lowering drug prices is the number one healthcare issue for voters — and elected officials are going to continue to hear from their constituents until drug prices are more affordable.”

“We urge the new administration and the new Congress to immediately address the rising cost of healthcare by delivering solutions that increase transparency, competition and value in the prescription drug market, and we look forward to working together to make drugs more affordable for citizens across the country.”

“The addition of the well-respected Society of General Internal Medicine is crucial as CSRxP continues to build a broad partnership of leaders from every corner of healthcare that are dedicated to fixing the broken prescription drug market,” said CSRxP Executive Director John Rother.

“Right now, the most pressing healthcare issue for voters is making prescription drugs affordable for those who need them. Voters are expecting action from the next president and their newly-elected Congress to fix this problem.”

“Rising drug prices are making trips to the hospital more expensive no matter where you live,” said John Rother, executive director of the Campaign for Sustainable Rx Pricing (CSRxP). “It’s price gouging on the most vulnerable, pure and simple, and Americans are fed up.”

“The consequences of unaccountable price increases for EpiPens are felt every day by millions of families across the country. Sadly, this is just the latest example of drug companies trying to justify their skyrocketing price increases.”

Our new fact sheet illustrates how EpiPens as one example of many where drug companies institute major price hikes that compound year after year.